Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04340986

Cohort of Patients With Hepatocellular Carcinoma or Cholangiocarcinoma

The main objective is to describe the evolution of patients treated for a primary malignant hepatobiliary tumor (hepatocellular carcinoma or cholangiocarcinoma) over the long course.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Cholangiocarcinoma Adenocarcinoma Carcinoma Carcinoma, Hepatocellular Digestive System Diseases Digestive System Neoplasms Hepatocellular Carcinoma Liver Diseases Liver Neoplasms Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Glandular and Epithelial

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Serviec hépatologie-Hôpital Saint Antoine

Paris, 75012, France

Location status: Recruiting

Location contact

Marie LEQUOY, MD

CONTACT

[email protected]

+330149283154

About this study

The collection of data from patients with CHC and cholangiocarcinomas who are cancers with poor prognosis is a major challenge to improve patients'care (diagnosis, prognosis); facilitate the search for new therapeutic targets and the follow-up of clinical studies; and develop personalized treatments.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Inclusion criteria

  • Age ≥ 18 years olds
  • Medical care in Nephrology department since 2015

Cholangiocarcinoma:

  • Histologically and cytologically documented cholangiocarcinoma, regardless of the stage of the disease

Hepatocellular carcinoma:

  • Hepatocellular carcinoma at any stage of the disease, presenting the diagnostic criteria according to the diagnostic criteria of Barcelona : Tumor of more than 1 cm, developed on cirrhosis liver with arterial phase hyperenhancement and washout in the portal venous or delayed phases on CT and MRI
  • Hepatocellular histologically documented

Exclusion criteria

  • Lack of patient non-opposition

Treatment and study plan

Primary outcomes

  1. Overall survival

    Time frame: 5 years

    Hepatocellular carcinoma and Cholangiocarcinoma : Overall survival is defined as the survival 5 years after the inclusion.

Secondary outcomes

  1. Overall survival

    Time frame: 5 years

    Hepatocellular carcinoma :Overall survival is defined as the survival after 5 years of inclusion.

  2. Disease free survival

    Time frame: 2 and 5 years

    Cholangiocarcinoma : 2 and 5 years after surgical resection

  3. Progression time under chemotherapy

    Time frame: Time of progression under chemotherapy up to 5 years

    Cholangiocarcinoma : Time of progression under chemotherapy is defined by the delay between the start of chemotherapy and tumor progression (appearance of a new lesion or increase in size of more than 30%)

Study contacts

Contact information is provided by the study sponsor or research team.

Marie LEQUOY, MD

CONTACT

[email protected]

+330149283154

Sponsors and collaborators

Lead sponsor

Assistance Publique - Hôpitaux de Paris

Other

Registry information

Official study title

Cohort Study of Patients With Primary Hepatocellular Carcinoma or Cholangiocarcinoma

Acronym: CHC/CC

Important dates

Study start
2020
Primary completion
2030
Study completion
2030
First posted
Apr 10, 2020
Registry last updated
Jun 20, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.